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Photodynamic therapy (PDT) is a treatment modality that has been used in the successful treatment of a number of diseases
and disorders, including age-related macular degeneration (AMD), psoriasis, and certain cancers. PDT uses a combination of a
selectively localised light-sensitive drug (known as a photosensitiser) and light of an appropriate wavelength. The light-activated
form of the drug reacts with molecular oxygen to produce reactive oxygen species (ROS) and radicals; in a biological environment
these toxic species can interact with cellular constituents causing biochemical disruption to the cell. If the homeostasis of the
cell is altered signiﬁcantly then the cell enters the process of cell death. The ﬁrst photosensitiser to gain regulatory approval for
clinical PDT was Photofrin. Unfortunately, Photofrin has a number of associated disadvantages, particularly pro-longed patient
photosensitivity. To try and overcome these disadvantages second and third generation photosensitisers have been developed and
investigated. This Review highlights the key photosensitisers investigated, with particular attention paid to the metallated and
non-metallated cyclic tetrapyrrolic derivatives that have been studied in vitro and in vivo; those which have entered clinical trials;
and those that are currently in use in the clinic for PDT.
Copyright © 2008 Leanne B. Josefsen and Ross W. Boyle. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. PHOTODYNAMIC THERAPY: BACKGROUND
The use of light in the treatment of disease has been known
for many centuries and can be traced back over 4000 years
to the ancient Egyptians [1]. The Egyptian people used a
combination of the orally ingested Amni Majus plant and
sunlight to successfully manage vitiligo: a skin disorder of
unknowncause.Theactiveingredientofthisplant(psoralen,
Figure 1) is now successfully employed in the worldwide
treatment of psoriasis [1–4].
Photodynamic therapy (PDT) is a treatment involving
light and a chemical substance (a photosensitiser), used in
conjunction with molecular oxygen to elicit cell death. More
explicitly, photodynamic therapy is a selective treatment
modality forthelocaldestructionof diseased cellsand tissue.
The selectivity is based on the ability of the photosensitiser
to preferentially accumulate in the diseased tissue and
eﬃciently generate singlet oxygen or other highly reactive
species such as radicals, which induce target cell death.
The principle of photodynamic therapy is based on
a multi-stage process (Figure 2). The ﬁrst of these stages
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Figure 1: Structure of psoralen.
(Figure 2(a)) sees the administration of a photosensitiser
with negligible dark toxicity, either systemically or topically,
in the absence of light. When the optimum ratio of
photosensitiser in diseased versus healthy tissue is achieved,
the photosensitiser is (Figure 2(c))a ct i v a t e db ye x p o s u r et oa
carefully regulated dose of light which is shone directly onto
the diseased tissue for a speciﬁed length of time. The light
dose is regulated in order to allow a suﬃcient amount of
energy to be delivered to activate the photosensitiser, but at
the same time the dose should be small enough to minimise
damage inﬂicted on neighbouring healthy tissue. It is the
activated form of the photosensitiser which evokes a toxic
response in the tissue, resulting in cell death. The success of
photodynamic therapy lies in the prolonged accumulation of2 Metal-Based Drugs
(a) Photosensitiser delivery (b) Selective accumulation in diseased tissue
hν
(c) Light irradiation (d) Selective destruction of diseased tissue
Figure 2: Photosensitiser administration.
photosensitiser in diseased tissue, relative to the more rapid
c l e a r a n c ef r o mn o r m a lt i s s u ec e l l s .
Photodynamic therapy is commonly practiced in the
treatment of a number of cancers, including those present
in the head and neck, the lungs, bladder, and particular
skin cancers [5–16]. It has also been successfully used in the
treatment of non-cancerous conditions such as age-related
macular degeneration (AMD), psoriasis, atherosclerosis, and
has shown some eﬃcacy in anti-viral treatments including
herpes [2, 3, 5–7, 9, 17–20].
Photodynamic therapy carries advantages for both the
patient and the physician: the need for delicate surgery and
lengthy recuperation periods is minimised, along with min-
imal formation of scar tissue and disﬁgurement. However,
photodynamic therapy is not without its drawbacks: a major
limitation is the associated general photosensitisation of skin
tissue.
2. HISTORY OF PHOTODYNAMIC THERAPY
Reports of contemporary photodynamic therapy came ﬁrst
in the investigations led by Finsen in the late nineteenth
century [8]. Finsen successfully demonstrated phototherapy
by employing heat-ﬁltered light from a carbon-arc lamp (the
“Finsen lamp”) in the treatment of a tubercular condition
of the skin known as lupus vulgaris, for which he won the
Nobel Prize in Physiology or Medicine in 1903 [8]. But it
was not until the early twentieth century that reports of
photodynamic therapy for the treatment of cancer patients
(with solid tumours) were made by von Tappeiner’s group in
Munich[2,4,6,9].In1913anotherGermanscientist,Meyer-
Betz, described the major stumbling block of photodynamic
therapy. After injecting himself with haematoporphyrin
(Hp, a photosensitiser), he swiftly experienced a general
skin sensitivity upon exposure to sunlight—a problem still
persistent with many of todays’ photosensitisers [2, 3, 7, 18].
Further studies, investigating the accumulation of
haematoporphyrin and the puriﬁed haematoporphyrin
derivative (HpD) in tumours, culminated in the late 1980s
with the photosensitiser Photofrin (Figure 3). A photosensi-
tiserwhich,afterfurtherpuriﬁcation,wasﬁrstgivenapproval
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Figure 3: Structure of Photofrin, n = 1–9.
in1993bytheCanadianhealthagencyforuseagainstbladder
cancer and later in Japan, USA and parts of Europe for use
against certain cancers of the oesophagus and non-small cell
lung cancer [3–9, 17, 18, 21, 22].
Photofrin was far from ideal and carried with it the
disadvantages of prolonged patient photosensitivity and a
weak long-wavelength absorption (630nm) [6, 7, 21]. This
led to the development of improved (second generation)
photosensitisers, including Verteporﬁn (a benzoporphyrin
derivative, also known as Visudyne) and more recently,
third generation photosensitisers based around targeting
strategies, such as antibody-directed photosensitisers [4, 5,
7, 18, 19, 23–25].
3. CYCLIC TETRAPYRROLIC CHROMOPHORES
AND PHOTOSENSITISERS
Cyclic tetrapyrrolic molecules are good examples of ﬂuo-
rophores (see Glossary) and photosensitisers. Photosensi-
tisers are molecules, which, when excited by light energy,
can utilise the energy to induce photochemical reactions toLeanne B. Josefsen and Ross W. Boyle 3
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Figure 4: Photosensitiser initiated cell death.
Apoptosis: a form of programmed cell death (often referred to as cell suicide) in response to key
physiological cues and intracellular damage. In apoptosis, the orchestrated collapse of a cell is
characterised by key morphological and biochemical changes followed by rapid engulfment of cellular
remains by neighbouring cells (phagocytosis). These key changes include maintenance of adenosine
triphosphate (ATP) levels, caspase activation, membrane blebbing, cell shrinkage, chromatin
condensation, DNA fragmentation, and the formation of small intact fragments (apoptotic bodies).
Apoptosis can be distinguished from necrotic cell death by the distinct absence of an associated
inﬂammatory response.
Necrosis: an uncontrolled form of cell death. A less ordered process than apoptosis and usually in
response to injurious agents such as infection, physical injury, ischemia (deﬁciency of oxygenated
blood), or excessive accumulation of ROS. In contrast to apoptosis, a local inﬂammatory response is
normally observed as a result of cellular debris released directly into surrounding tissue.
Box 1
produce lethal toxic agents. In a cellular environment, these
agents (reactive oxygen species (ROS) and radicals) ulti-
mately result in cell death and tissue destruction (Figure 4)
[5–9]. Photosensitisers are absorbed into cells all over the
body and alone are harmless, that is, in the absence of
light, and usually oxygen they have no eﬀect on healthy or
abnormal tissue. Ideally, they should be retained by diseased
tissue, particularly tumours, for longer periods of time in
comparison to healthy tissue; thus it is important to carefully
time light exposure and ensure that activation only occurs
when the ratio of photosensitiser is greater in diseased tissue
thanin healthy tissue, therebyminimising unwanteddamage
to surrounding non-cancerous cells [3, 19].
Photosensitisers also have alternative applications. They
have been employed in the sterilisation of blood plasma and
water in order to remove blood-borne viruses and microbes
and have been considered for agricultural uses, including
herbicides and insecticides [5, 9, 26–28].
4. PHOTOCHEMISTRY:
PHOTOCHEMICAL PROCESSES
Only when a photosensitiser is in its excited state (3Psen∗)
can it interact with molecular oxygen (3O2)a n dp r o d u c e
radicals and activated oxygen species (ROS), crucial to the
Type II mechanism which is thought to predominate in
PDT (see below). These species include singlet oxygen (1O2),
hydroxyl radicals (•OH), and superoxide (O2
−)i o n sa n d
can interact with cellular components including unsaturated
lipids; amino acid residues; and nucleic acids. If suﬃcient
oxidative damage ensues, this will result in target-cell death
(only within the immediate area of light illumination).
5. PHOTOCHEMICAL MECHANISMS
When a chromophore, such as a cyclic tetrapyrrolic
molecule, absorbs a photon of electromagnetic radiation in
the form of light energy, an electron is promoted into a
higher-energy molecular orbital, elevating the chromophore
from the ground state (S0) into a short-lived, electronically
excited state (Sn)c o m p o s e do fan u m b e ro fv i b r a t i o n a l
sub-levels (S
 
n). The excited chromophore can lose energy
by rapidly decaying through these sub-levels via internal
conversion(IC)topopulatetheﬁrstexcitedsingletstate(S1),
before quickly relaxing back to the ground state (Figure 5).
The decay from the excited singlet state (S1) to the
ground state (S0)i svia ﬂuorescence (S1 → S0). Singlet
state lifetimes of excited ﬂuorophores are very short (τﬂ. =
10−9–10−6 seconds) since transitions between the same spin
states (S → So rT→ T) conserve the spin multiplicity
of the electron and, according to the Spin Selection Rules,
are therefore considered “allowed” transitions [3, 6, 8].
Alternatively, an excited singlet state electron (S1)c a n
undergo spin inversion and populate the lower-energy ﬁrst4 Metal-Based Drugs
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Figure 5: Modiﬁed Jablonski energy diagram.
QuantumYields
Photochemicalquantumyields(Φ)areoneofthekeymeasurementsmadeinthephotochemical
techniques described above. According to the Stark-Einstein law:
“every photon absorbed by a species excites only one molecule of the species.” Later
reﬁned to: “one particle is excited for each quanta of radiation absorbed” (Second Law of
Photochemistry).
The quantum yield can therefore be described as the number of molecules undergoing the pro-
cess of interest (formation of product or consumption of reactants) for each quantum of radia-
tion energy absorbed (equation 1):
Φ =
number of species undergoing process of interest
number of photons absorbed
Equation 1: Quantum Yields
Quantum yields may also be expressed in terms of the rate of the reaction:
Φ =
rate of chemical process/event
intensity of absorbed light
=
d[x]/dt
Iabs
Thequantumyield(s)foraspeciescannotbegreaterthanunity(Φ ≤ 1)unlessasecondaryreac-
tion or a series of chain reactions are taking place within the sample, in which case the quantum
yields are respectively Φ ≤ 2a n dΦ ≥ 2.
Singlet Oxygen QuantumYields
Ifthefractionofexcitedtripletstatemoleculesquenchedbymolecularoxygentoproducesinglet
oxygen (1Δg)i sr e p r e s e n t e da sS Δ, the quantum yield of singlet oxygen (ΦΔ) can be determined
(equation 2):
ΦΔ = ΦTSΔ
Equation 2: Singlet Oxygen Quantum Yield
Box 2
excited triplet state (T1) via intersystem crossing (ISC); a
spin-forbidden process, since the spin of the electron is no
longer conserved [29–34]. The excited electron can then
undergo a second spin-forbidden inversion and depopulate
the excited triplet state (T1) by decaying back to the ground
state (S0) viaphosphorescence (T1 → S0)[ 29–34]. Owing to
the spin-forbidden triplet to singlet transition, the lifetime
of phosphorescence (τP = 10
−3 − 1 second) is considerably
longer than that of ﬂuorescence.
6. PHOTOSENSITISERS AND PHOTOCHEMISTRY
Tetrapyrrolic photosensitisers in the excited singlet state
(1Psen∗,S >0) are relatively eﬃcient at undergoing inter-
system crossing and can consequently have a high triplet-
state quantum yield, Box 2 (ΦT 0.62 (tetraphenylporphyrin
(TPP), methanol)), 0.83 (etiopurpurin, benzene), 0.71
(tetrasulphonated TPP, D2O), and 0.47 (tetrasulphonated
zinc phthalocyanine, methanol)) [8, 35, 36]. The longerLeanne B. Josefsen and Ross W. Boyle 5
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Figure 6: Type-I process (i).
lifetime of this species is suﬃcient to allow the excited
tripletstatephotosensitiser tointeractwithsurrounding bio-
molecules, including cell membrane constituents [5, 17].
7. PHOTOCHEMICAL REACTIONS
Excited triplet-state photosensitisers can react in two ways
deﬁnedasType-IandType-IIprocesses.Type-Iprocessescan
involve the excited singlet or triplet photosensitiser (1Psen∗,
S1; 3Psen∗,T 1), however due to the short lifetime of the
excited singlet state, the photosensitiser can only react if it
is intimately associated with a substrate, in both cases the
interaction is with readily oxidisable or reducable substrates.
Type-II processes involve the direct interaction of the excited
triplet photosensitiser (3Psen∗,T 1) with molecular oxygen
(3O2, 3Σg)[ 5–8, 17, 18, 37].
Type-I processes can be divided into two further mecha-
nisms;TypeI(i)andTypeI(ii).Theﬁrstofthesemechanisms
(i) involves the transfer of an electron (oxidation) from
a substrate molecule to the excited state photosensitiser
(Psen∗), generating a photosensitiser radical anion (Psen
•−)
and a substrate radical cation (Subs
•+). The majority
of the radicals produced from Type-I(i) reactions react
instantaneously with oxygen, generating a complex mixture
of oxygen intermediates. For example, the photosensitiser
radical anion can react instantaneously with molecular
oxygen (3O2) to generate a superoxide radical anion (O2
•−),
which can go on to produce the highly reactive hydroxyl
radical (OH
•, Figure 6), initiating a cascade of cytotoxic free
radicals; this process is common in the oxidative damage
of fatty acids and other lipids [17, 18]. Some of the more
common Type-I(i) reactions are shown in Figure 6.
The second Type-I process (ii) involves the transfer of a
hydrogen atom (reduction) to the excited state photosensi-
tiser (Psen∗). This generates free radicals capable of rapidly
reacting with molecular oxygen and creating a complex
mixture of reactive oxygen intermediates, including reactive
peroxides (Figure 7). Once again, this can trigger a torrent of
cytotoxic events, culminating in cell damage and death.
On the other hand, Type-II processes involve the
direct interaction of the excited triplet state photosensitiser
(3Psen∗) with ground state molecular oxygen (3O2, 3Σg,
Figure 8); a spin allowed transition—the excited state photo-
sensitiser and ground state molecular oxygen are of the same
spin state (T, Figure 5).
Psen∗ +R - H
R• +O 2
RO2
• +R - H
Psen-H• +R •
RO2
•
RO2H+ R •
Figure 7: Type-I process (ii).
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Figure 8: Type-II process.
When the excited photosensitiser collides with a
molecule of molecular oxygen, a process of triplet-triplet
annihilation takes place (3Psen∗ →1Psen and 3O2 →1O2).
This inverts the spin of one of molecular oxygens (3O2)
outermost antibonding electrons, generating two forms of
singlet oxygen (1Δg and 1Σg, Figure 9), while simultaneously
depopulating the photosensitiser’s excited triplet state (T1 →
S0, Figure 5). The higher-energy singlet oxygen state (1Σg,
157kJ mol
−1 > 3Σg) is very short-lived (1Σg ≤ 0.33 millisec-
onds (methanol), undetectable in H2O/D2O) and rapidly
relaxes to the lower-energy excited state (1Δg,9 4k Jm o l
−1 >
3Σg)[ 36]. It is, therefore, this lower-energy form of singlet
oxygen (1Δg) which is implicated in cell injury and cell death
[38].
The highly-reactive oxygen species (1O2)p r o d u c e dvia
the Type-II process act near to their site of generation
and within a radius of action of approximately 20nm,
with a typical lifetime of approximately 40 nanoseconds
in biological systems [2, 7, 17]. However, it has recently
been suggested that (over a 6 microsecond period) singlet
oxygen can diﬀuse up to approximately 300nm in vivo
[39–41]. Singlet oxygen can theoretically only interact with
proximal molecules and structures within this radius [17].
ROS are known to initiate a large number of reactions with
biomolecules, including amino acid residues in proteins,
such as tryptophan; unsaturated lipids like cholesterol and
nucleic acid bases, particularly guanosine and guanine
derivatives (Box 3) with the latter base more susceptible to
ROS [2,5,8,17,36,42–45].Theseinteractionscausedamage
andpotentialdestructiontocellularmembranesandenzyme
deactivation, culminating in cell death [8].
It is highly probable that in the presence of molecular
oxygen, and as a direct result of the photoirradiation of
the photosensitiser molecule, both Type-I and II pathways
play a pivotal role in disrupting cellular mechanisms and
cellular structure. Nevertheless, there is considerable evi-
dence to suggest that the Type-II photo-oxygenation process
predominates in the induction of cell damage, a consequence
of the interaction between the irradiated photosensitiser and
molecular oxygen [2, 5, 8, 18, 43, 46]. It has been suggested,
however, that cells in vivo are partially protected against
the eﬀects of photodynamic therapy by the presence of
singlet oxygen scavengers (such as histidine) and that certain
skin cells are somewhat resistant to photodynamic therapy
in the absence of molecular oxygen; further supporting6 Metal-Based Drugs
Typical Singlet Oxygen Reactions
Singlet molecular oxygen is known to react with systems by attacking electron rich double bonds, in an “-ene” type reaction, to form
peroxides or hydroperoxides.
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Figure 9: Molecular orbital diagram of oxygen (3Σg, 1Δg,a n d1Σg).
the proposal that the Type-II process is at the heart of
photoinitiated cell death [17, 43, 47, 48].
NN
Cu
N N N
Cl
Figure 10: A copper metallated photosensitiser.
The eﬃciency of Type-II processes is dependent upon
the triplet state lifetime τT (see Glossary, under lumines-
cence life time) and the triplet quantum yield (ΦT)o f
the photosensitiser. Both of these parameters have been
implicated in the eﬀectiveness of a photosensitiser in pho-
totherapeutic medicine; further supporting the distinction
between Type-I and Type-II mechanisms. However, it is
worthy to note that the success of a photosensitiser is not
exclusively dependent upon a Type-II process taking place.
There are a number of photosensitisers whose excited triplet
lifetimes are too short to permit a Type-II process to occur.
For example, the copper metallated octaethylbenzochlorin
photosensitiser (Figure 10) has a triplet state lifetime of lessLeanne B. Josefsen and Ross W. Boyle 7
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Figure 11: Examples of non-porphyrinic photosensitisers.
than 20 nanoseconds and is still deemed to be an eﬃcient
photodynamic agent [13, 43].
8. PHOTOSENSITISERS—IDEAL PHOTOSENSITISERS
Although a number of diﬀerent photosensitising com-
pounds, such as methylene blue (see Glossary), rose bengal,
and acridine (Figure 11), are known to be eﬃcient singlet
oxygen generators (and therefore potential photodynamic
therapy agents), a large number of photosensitisers are
cyclic tetrapyrroles or structural derivatives of this chro-
mophore; in particular porphyrin, chlorin, bacteriochlorin,
expanded porphyrin, and phthalocyanine (PCs) derivatives
(Figure 12). This is possibly because cyclic tetrapyrrolic
derivatives haveaninherentsimilarity tothenaturallyoccur-
ring porphyrins present in living matter—consequently they
have little or no toxicity in the absence of light [2, 5, 17, 18,
36, 44, 49].
Porphyrins are a group of naturally occurring and
intensely coloured compounds, whose name is drawn from
theGreekwordporphura,theGreekwordforpurple[50,51].
These molecules are known to be involved in a number of
biologically important roles, including oxygen transport and
photosynthesis, and have applications in a number of ﬁelds,
rangingfromﬂuorescenceimagingtomedicine[2,5,17,42].
Porphyrins are classiﬁed as tetrapyrrolic molecules, with the
heart of the skeleton a heterocyclic macrocycle, known as a
porphine. The fundamental porphine frame consists of four
pyrrolic sub-units linked on opposing sides (α-positions,
numbered 1, 4, 6, 9, 11, 14, 16, and 19, Figure 13) through
four methine (CH) bridges (5, 10, 15, and 20), known as
the meso-carbon atoms/positions (Figure 13). The resulting
conjugated planar macrocycle may be substituted at the
meso- and/or β-positions (2, 3, 7, 8, 12, 13, 17, and 18): if the
meso- and β-hydrogens are substituted with non-hydrogen
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Figure 13: Porphine macrocycle.
atoms or groups, the resulting compounds are known as
porphyrins.
The inner two protons of a free-base porphyrin can
be removed by strong bases such as alkoxides, forming a
dianionic molecule; conversely, the inner two pyrrolenine
nitrogenscanbeprotonatedwithacidssuchastriﬂuoroacetic
acid aﬀording a dicationic intermediate (Figure 14). The8 Metal-Based Drugs
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tetradentate anionic species can readily form complexes with
most metals.
9. PORPHYRIN ABSORPTION SPECTROSCOPY
On account of their highly conjugated skeleton, porphyrins
have a characteristic ultra-violet visible (UV-VIS) spectrum
(Figure 15). The spectrum typically consists of an intense,
narrow absorption band (ε>200000lmol−1cm−1)a t
around 400nm, known as the Soret or B band, followed by
four longer wavelength (450–700nm), weaker absorptions
(ε>20000lmol−1cm−1 (free-base porphyrins)) referred to
as the Q bands [6, 17, 50, 53, 54].
The Soret band arises from a strong electronic transition
from the (porphyrin) ground state to the second excited
singlet state (S0 → S2, Figure 16); whereas the Q band is a
result of a weak transition to the ﬁrst excited singlet state
(S0 → S1). The dissipation of energy via internal conversion
(IC) is so rapid that ﬂuorescence is only observed from
depopulation of the ﬁrst excited singlet state to the lower-
energy ground state (S1 → S0).
10. SECOND-GENERATION PHOTOSENSITISERS
10.1. Idealphotosensitiserproperties
The key characteristic of any photodynamic sensitiser is
its ability to preferentially accumulate in diseased tissue
and, via the generation of cytotoxic species, induce a
desired biological eﬀect. In particular, a good photodynamic
sensitiser should adhere to the following criteria:
(i) have strong absorption with a high extinction coef-
ﬁcient in the red/near infrared region of the elec-
tromagnetic spectrum (600–850nm)—allows deeper
tissue penetration by light [5–7, 17, 36, 43],
(ii) be eﬀective generators of singlet oxygen and other
ROS,
(iii) have suitable photophysical characteristics: a high-
quantumyieldoftripletformation(ΦT ≥ 0.5);ahigh
singlet oxygen quantum yield (ΦΔ ≥ 0.5); a relatively
long triplet state lifetime (τT, microsecond range);
and a high triplet-state energy (≥94KJmol−1)[ 3, 8,
18, 36, 56]. To date the parameters ΦT = 0.83 and
ΦΔ = 0.65 (haematoporphyrin); ΦT = 0.83 and
ΦΔ = 0.72 (etiopurpurin); and ΦT = 0.96 and ΦΔ =
0.82 (tin etiopurpurin) have been achieved [2, 36],
(iv) have minimum dark toxicity and negligible cytotoxi-
city in the absence of light,
(v) exhibitgreaterretentionindiseased/targettissueover
healthy tissue,
(vi) present rapid clearance from the body,
(vii) be single, well-characterised compounds, with a
known and constant composition,
(viii) have a short and high yielding synthetic route (with
easy translation into multi-gram scales/reactions),
(ix) have a simple and stable drug formulation,Leanne B. Josefsen and Ross W. Boyle 9
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(x) be soluble in biological media, allowing direct intra-
venous administration and transport to the intended
target. Failing this, a hydrophilic delivery system
should be sought enabling eﬃcient and eﬀective
transportation of the photosensitiser to the target site
via the bloodstream.
While the major disadvantages associated with the ﬁrst
generation photosensitisers HpD and Photofrin (skin sensi-
tivity and weak absorption at 630nm) have not prevented
the treatment of some cancers and other diseases, they
have markedly reduced the successful application of these
photosensitisers to a wider ﬁeld of disease. The development
of second generation photosensitisers, designed to minimise
the drawbacks of the ﬁrst generation photosensitisers, was
key to the development of photodynamic therapy. A number
of new photosensitisers were therefore developed to over-
come these short comings.
5-Aminolaevulinicacid
5-Aminolaevulinic acid (ALA) is a prodrug used in the
clinic to treat and image a number of superﬁcial cancers
and tumours (see Tables 2 and 3)[ 5–9, 11, 17, 18]. ALA
on its own is not a photosensitiser, but a key precursor in
the biosynthesis of the naturally occurring porphyrin, haem
(Scheme 1).
Haem is synthesised in every energy-producing cell in
the body and is a key structural component of haemoglobin,
myoglobin, and other haemproteins. The immediate
precursor to haem is protoporphyrin IX (PPIX), an eﬀective
photosensitiser. Haem itself is not a photosensitiser, due to
the coordination of a paramagnetic ion (iron; see Glossary;
see also diamagnetic species) in the centre of the macrocycle,
causing signiﬁcant reduction in excited state lifetimes
[5–9, 11].
The haem molecule is synthesised from glycine and
succinyl coenzyme A (succinyl CoA). The rate-limiting step
inthebiosynthesispathwayiscontrolledbyatight(negative)
feedback mechanism in which the concentration of haem
regulates the production of ALA. However, this controlled
feedback can be by-passed by artiﬁcially adding excess
exogenous ALA to cells. The cells respond by producing
PPIX (photosensitiser) at a faster rate than the ferrochelatase
enzyme can convert it to haem [5–9, 11, 17, 18].
ALA, marketed as Levulan (DUSA Pharmaceuticals
Incorporated, Toronto, Canada), has shown promise in10 Metal-Based Drugs
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photodynamic therapy (tumours) via both intravenous and
oral administration, as well as through topical administra-
tion in the treatment of malignant and non-malignant der-
matological conditions, including psoriasis, Bowen’s disease,
and Hirsutism (Phase II/III clinical trials, see Glossary) [5–
9, 11, 18].
ALA shows a more rapid accumulation in comparison to
other intravenously administered sensitisers [5–9, 11]. Typi-
calpeaktumouraccumulationlevelspost-administrationfor
PPIX are usually achieved within several hours; compare this
with other (intravenously administered) photosensitisers
which may take up to 96 hours to reach peak levels and one
of the main advantages of ALA can be clearly seen. ALA is
also excreted more rapidly from the body (∼24 hours) than
other photosensitisers, minimising patient photosensitivity
[5–8, 11].
In an attempt to overcome the poor bioavailability when
ALA is applied topically, esteriﬁed ALA derivatives with
improved pharmacological properties have been examined
[5–8, 11]. A methyl ALA ester (Metvix) is now being
marketed by Photocure ASA (Oslo, Norway) as a potential
photosensitiser for basal cell carcinoma and other skin
lesions [5, 6, 9, 17]. Benzyl (Benvix) and hexyl ester (Hexvix)
derivatives are also registered by Photocure ASA for the
treatment of gastrointestinal cancers and for the diagnosis of
bladder cancer [9].
Verteporﬁn
The second generation photosensitiser, benzoporphyrin
derivative monoacid ring A (BPD-MA, Figure 17)h a sb e e n
developed by QLT Phototherapeutics (Vancouver, Canada)
under the trade name Visudyne (Verteporﬁn, for injection)
and,in collaborationwithCibaVision Corporation (Duluth,
GA, USA), has undergone Phase III clinical trials (USA)
for the photodynamic treatment of wet age-related macular
degeneration (AMD, see Glossary) and cutaneous non-
melanoma skin cancer [3, 5–7, 9, 57–59]. Verteporﬁn is cur-
rently marketed by Novartis Pharmaceuticals Corporation
(NJ, USA).
N HN
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Figure 19: Foscan.
The chromophore of BPD-MA has a red-shifted and
intensiﬁed long-wavelength absorption maxima at approxi-
mately690nm.Tissuepenetrationbylightatthiswavelength
is 50% greater than that achieved for Photofrin (λmax. =
630nm) [5, 60].
Verteporﬁn has further advantages over the ﬁrst genera-
tionsensitiserPhotofrin.Itisrapidlyabsorbedbythetumour
(optimal tumour-normal tissue ratio 30–150 minutes post-
intravenous injection) and is rapidly cleared from the body,
minimising patient photosensitivity (1-2 days) [5, 61].
Purlytin
Tin etiopurpurin, a chlorin photosensitiser (Figure 18),
i sm a r k e t e du n d e rt h et r a d en a m eP u r l y t i nb yM i r a v a n t
Medical Technologies (Santa Barbara, Calif, USA) [5–9, 62].
Purlytin has also undergone Phase II clinical trials (USA) for
cutaneous metastatic breast cancer and Kaposi’s sarcoma in
patients with AIDS (acquired immunodeﬁciency syndrome)
[3, 7]. Purlytin has been used successfully to treat the non-
malignant conditions psoriasis and restenosis [5].
Chlorins (Figure 12) are distinguished from the parent
porphyrins by a reduced exocyclic double bond. The result
of the reduced bond is a decrease in the symmetry of the
conjugated macrocycle, leading to an increased absorption
in the long-wavelength portion of the visible region of
theelectromagneticspectrum(650–680nm).Morecorrectly,
Purlytin is a purpurin; a degradation product of chlorophyll
[8, 9, 12].
Purlytinhasatinatomchelatedinitscentralcavitywhich
causes a red-shift of approximately 20–30nm (with respect
to Photofrin and non-metallated etiopurpurin, λmax.SnEt2 =
650nm) [6, 9, 12]. Purlytin has been reported to localise
in skin and produce a photoreaction 7–14 days post-
administration [6, 9].
Foscan
Tetra(m-hydroxyphenyl)chlorin (mTHPC, Figure 19)h a s
been developed and entered into clinical trials (USA
and Europe) under the trade name Foscan by ScotiaLeanne B. Josefsen and Ross W. Boyle 11
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Pharmaceutics(Guildford,Surrey,UK)andBioLitecPharma
Limited (Dublin, Ireland) [3, 5–9, 11, 18]. Foscan, also
known as Temoporﬁn, has been evaluated as a photothera-
peutic agent against head and neck cancers in these trials [5].
It has also been investigated in clinical trials for malignant
andnon-malignantdiseases,includinggastricandpancreatic
cancers, hyperplasia, ﬁeld sterilisation after cancer surgery
and for the control of antibiotic-resistant bacteria, in the
USA, Europe, and the Far East [5, 9, 11].
Foscan has a singlet oxygen quantum yield comparable
to other chlorin photosensitisers but the low drug and light
doses (approximately 0.1mgkg−1 and as low as 5Jcm−2,
resp.) required to achieve photodynamic responses (equiv-
alent to Photofrin, 2–5mgkg−1, 100–200Jcm−2; therefore
Foscan is approximately 100 times more photoactive than
Photofrin), potentially make Foscan one of the most potent
second generation photosensitisers currently under investi-
gation [5, 7, 9].
Unfortunately, Foscan can render patients photosensitive
for up to 20 days after initial illumination [6, 63, 64]. One
solution to this problem would be to use lower drug doses.
Lutex
Lutetium texaphyrin, marketed under the trade name Lutex
and Lutrin (Pharmacyclics, Calif, USA), is a “texas-sized”
porphyrin [5–9, 18, 65, 66]. Texaphyrins (ﬁrst synthesised
in 1987 by Sessler and his group) are expanded porphyrins
that have a penta-aza core (Figure 20). The result of this
macrocyclic modiﬁcation is a strong absorption in the 730–
770nm region of the electromagnetic spectrum [9, 12]. This
region is particularly important since tissue transparency
is optimal in this range. As a result, Lutex-based PDT can
(potentially) be carried out more eﬀectively at greater depths
and on larger tumours [5, 6].
Lutex has entered Phase II clinical trials (USA) for
evaluation against breast cancer and malignant melanomas
[6, 67].
A Lutex derivative, Antrin, has also undergone Phase I
clinical trials (USA) for the prevention of restenosis (see
Glossary) of vessels after cardiac angioplasty by photoinac-
tivating foam cells that accumulate within arteriolar plaques
[6, 68]. A second Lutex derivative, Optrin, is in Phase I trials
for AMD [5].
Texaphyrins are being developed further by Phar-
macyclics as radiosensitisers (Xcytrin, see Glossary) and
chemosensitisers (see Glossary) [5]. Xcytrin, a gadolinium
texaphyrin (motexaﬁn gadolinium), has been evaluated in
Phase III clinical trials against brain metastases and Phase I
clinical trials (USA) for primary brain tumours [5].
ATMPn
9-Acetoxy-2,7,12,17-tetrakis-(β-methoxyethyl)-porphycene
(Figure 21) has been evaluated by Glaxo Dermatology
(GlaxoWellcome, NC, USA) and Cytopharm (Calif, USA)12 Metal-Based Drugs
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as a photodynamic therapy agent for dermatological
applications against psoriasis vulgaris and superﬁcial
non-melanoma skin cancer [5, 69–72].
ZincphthalocyanineCGP55847
Aliposomalformulationofzincphthalocyanine(CGP55847,
Figure 22), developed by QLT Phototherapeutics (Vancou-
ver, Canada) and sponsored by Ciba Geigy (Novartis,
Basel, Switzerland), has undergone clinical trials (Phase
I/II, Switzerland) against squamous cell carcinomas of the
upper aerodigestive tract [5, 18, 73, 74]. Phthalocyanines
(PCs) (Figure 12) are related to tetra-aza porphyrins. Instead
of four bridging carbon atoms at the meso-positions, as
for the porphyrins, PCs have four nitrogen atoms linking
the pyrrolic sub-units together. PCs further diﬀer from
porphyrins through the presence of an extended conjugate
pathway: a benzene ring is fused to the β-positions of each
of the four-pyrrolic sub-units. These benzene rings act to
strengthen the absorption of the chromophore at longer
wavelengths (with respect to porphyrins). The absorption
band of PCs is almost two orders of magnitude stronger
than the highest Q band of haematoporphyrin [12]. These
favourablecharacteristics,alongwiththeabilitytoselectively
functionalisetheirperipheralstructure,makePCsfavourable
photosensitiser candidates [10, 75–78].
A sulphonated aluminium PC derivative (Photosense,
Figure 23) has also entered clinical trials (Russian Academy
of Medical Sciences, and the surgical clinic of the Moscow
Medical Academy, Moscow, Russia) against skin, breast, and
NH
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Figure 24: A naphthalocyanine.
lung malignancies and cancer of the gastrointestinal tract [5,
18,79–81].SulphonationsigniﬁcantlyincreasesPCsolubility
in polar solvents including water, circumventing the need for
alternative delivery vehicles [9, 12, 18, 82].
A third PC under investigation is a silicon complex, PC4.
This photosensitiser is being examined for the sterilisation
of blood components at the New York Blood Centre (VI
Technologies Incorporated (Vitex), Melville, NY, USA),
againsthumancolon,breast,andovariancancersandagainst
glioma [5, 83–89].
A shortcoming of many of the metallo-PCs is their
tendencytoaggregateinaqueousbuﬀer(pH7.4),resultingin
a decrease, or total loss, of their photochemical activity. This
behaviour can be minimised in the presence of detergents
[12].
Metallated cationic porphyrazines (PZ), including
PdPZ+,C u P Z +, CdPZ+,M g P Z +, AlPZ+, and GaPZ+,h a v e
been developed and also tested in vitro on V-79 (Chinese
hamster lung ﬁbroblast) cells. Results have suggested these
photosensitisers are capable of inducing substantial dark
toxicity [12].
Naphthalocyanines
Naphthalocyanines (NCs, Figure 24) are an extended PC
derivative. They have an additional benzene ring attached
to each isoindole sub-unit on the periphery of the PC
structure. Subsequently, NCs absorb strongly at even longer
wavelengths (approximately 740–780nm) than PCs (670–
780nm), further increasing the depth NC photosensitisers
can be eﬀectively used at. This absorption in the near
infrared region makes NCs good candidates for photody-
namic treatment of highly pigmented tumours, including
melanomas, which present signiﬁcant problems with respect
to transmission of visible light.
However, a number of problems are associated with NC
photosensitisers. NCs are generally less stable than their PC
relatives: they readily decompose in the presence of light
and oxygen; and metallo-NCs, which lack axial ligands,
have a tendency to form H-aggregates in solution [12, 90].
These aggregates are photoinactive, thus compromising the
photodynamic eﬃcacy of NCs [12]. The main investigationsLeanne B. Josefsen and Ross W. Boyle 13
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into NCs as photodynamic therapy agents have been carried
out by Kenney and co-workers, van Lier’s group and the
Bulgarian Academy of Sciences (Soﬁa, Bulgaria) (see below).
Functionalgroups
Altering the peripheral functionality of porphyrin-type
chromophores can also have an eﬀect on photodynamic
activity.
Diamino platinum porphyrins show high anti-tumour
activity, demonstrating the combined eﬀect of the cytotox-
icity of the platinum complex and the photodynamic activity
of the porphyrin species [12, 91].
Positively charged PC derivatives have also been inves-
tigated [12, 64, 76, 77]. Cationic species are believed to
selectively localise in the vital sub-cellular organelle, the
mitochondrion. Mitochondria are key to the survival of a
cell; being the site of oxidative phosphorylation, and hence
are potentially important PDT targets.
Zinc and copper cationic derivatives have been investi-
gated. Although, the positively charged zinc complexed PC
was found to be less photodynamically active than its neutral
counterpart in vitro against V-79 cells [12].
Water-soluble cationic porphyrins bearing nitrophenyl,
aminophenyl, hydroxyphenyl, and/or pyridiniumyl func-
tional groups exhibit varying cytotoxicity to cancer cells in
vitro, depending on the nature of the metal ion (Mn, Fe,
Zn, Ni), and on the number and type of functional groups
[12, 77, 92]. The manganese pyridiniumyl derivative has
shown the highest photodynamic activity, while the nickel
analogue is photoinactive (Figure 25)[ 12, 92].
Another metallo-porphyrin complex, the iron chelate,
was found to be more photoactive (towards HIV and simian
immunodeﬁciency virus in MT-4 cells) than the manganese
complexes; the zinc derivative was found to be photoinactive
[12, 93].
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Figure 26: 5,10-Di-(4-sulphonatophenyl)-15,20-diphenylporphy-
rinato aluminium chloride.
The hydrophilic sulphonated porphyrins and PCs
(AlPorphyrin and AlPC) compounds were tested for pho-
todynamic activity [94]. The disulphonated analogues
(with adjacent substituted sulphonated groups, Figure 26)
exhibited greater photodynamic activity than their di-
(symmetrical), mono-, tri- and tetra-sulphonated counter-
parts; tumour activity increased with increasing degree of
sulphonation [8, 78].
11. THIRD-GENERATION PHOTOSENSITISERS
The poor solubility of many photosensitisers in aqueous
media, particularly at physiological pH, prevents their
intravenous delivery directly into the bloodstream. It would
be advantageous therefore, if a delivery model could be14 Metal-Based Drugs
conceived which would allow the transportation of these
(otherwise potentially useful) photosensitisers to the site of
diseased tissue.
Work has recently focused on designing systems to eﬀect
greater selectivity and speciﬁcity on the photosensitiser in
order to enhance cellular uptake [7, 38]. A number of
possible delivery strategies have been suggested, ranging
from the use of oil-in-water (o/w) emulsions to liposomes
and nanoparticles as potential carrier vehicles [3, 7, 18, 36,
95, 96]. There is concern however, that although the use of
these systems may increase the therapeutic eﬀect observed
as a result of photodynamic therapy, the carrier system
may inadvertently decrease the “observed” singlet oxygen
quantum yield (ΦΔ) of the encapsulated photosensitiser: the
singlet oxygen generated by the photosensitiser would have
to diﬀuse out of the carrier system; and since it (singlet
oxygen) is believed to have a narrow radius of action, singlet
oxygen may not reach the target and elicit its desired eﬀect
[18]. It may also be possible that, if the size of the carrier is
not suﬃciently small or that the carrier system does not fully
dissolve in physiological media, the incidence/exciting light
may not be appropriately absorbed and light scattering may
be signiﬁcant, thus inadvertently reducing the singlet oxygen
yield. An alternative delivery method which would remove
thisproblemistheuseoftargetingmoieties.Typicaltargeting
strategies have included the investigation of photosensitisers
directly attached to biologically active molecules such as
antibodies [23–25]. These third generation photosensitisers
are currently showing promise (in vitro) against colorectal
tumour cells [24].
Metallation
A wide range of metals have been used to form complexes
with photosensitiser macrocycles, with variable photody-
namic results. A number of the second generation photosen-
sitisers described earlier contain a chelated central metal ion.
The main metals which have been used are transition metals,
althoughanumberofphotosensitisersco-ordinatedtogroup
13(Al,AlPcS4)andgroup14(Si,SiNC,andSn,SnEt2)metals
have also been synthesised.
There seems to be no consistent observation as to
the potential success of metallated photosensitisers. Indeed,
a wide range of photosensitisers are metallated, but the
metal ion does not confer deﬁnite photoactivity on the
photosensitiser. Copper (II), cobalt (II), iron (II), and zinc
(II) complexes of Hp are all photoinactive in contrast to
metal-freeporphyrins[12].Yetthereversehasbeenobserved
for texaphyrin and PC photosensitisers; only the metallo-
complexes have demonstrated eﬃcient photosensitisation
[12].
The presence and nature of the central metal ion, bound
by a number of photosensitisers, strongly inﬂuences the
photophysical properties of the photosensitiser [12, 64, 77].
Chelation of paramagnetic metals to a PC chromophore
appears to shorten triplet lifetimes (down to nanosecond
range), generating variations in the triplet quantum yield
and triplet lifetime of the photoexcited triplet state of the
metallated PC (mPC) [12, 64, 77, 97].
Intersystem crossing (ISC) is an important parameter
of photosensitisers. The triplet quantum yield and lifetime
of a photosensitiser are directly related to the eﬃciency of
singlet oxygen generation; a key component in the success of
a photosensitiser [97].
Certain heavy metals are known to enhance ISC. Gen-
erally, diamagnetic metals promote ISC and have a long
triplet lifetime [64, 77, 97]. In contrast, paramagnetic species
deactivate excited states, reducing the excited-state lifetime
and preventing photochemical reactions from taking place
[97]. However, there are well-known exceptions to this
generalisation, including copper octaethylbenzochlorin [13].
For many of the metallated paramagnetic texaphyrin
species, triplet-state lifetimes are down in the nanosecond
range[97].TheseresultsarealsomirroredbymetallatedPCs.
PCs metallated with diamagnetic ions, such as Zn2+,A l 3+,
and Ga3+, generally yield photosensitisers with desirable
quantum yields and lifetimes (ΦT 0.56, 0.50 and 0.34 and τT
187, 126 and 35μs, resp.) [12, 97]. The ZnPC photosensitiser
(ZnPcS4) has a singlet oxygen quantum yield of 0.70; nearly
twice that of most other mPCs (ΦΔ at least 0.40) [12, 18].
Hence, the latter diamagnetic complexes should be strong
candidates for PDT.
Since the heavy metal eﬀect (see Glossary) is known
to promote ISC, theoretically, it should be possible to
enhance the photophysical properties (ΦT, ΦΔ,a n dτT)
of any photosensitiser via metallation. In practice, this is
not the case. Only one metallo-porphyrin photosensitiser
(copper octaethylbenzochlorin) has shown photodynamic
promise, the remaining eﬃcient porphyrin photosensitisers
are metal-free [13]. The reverse of this behaviour is observed
for PCs and texaphyrins; only the (diamagnetic) metallated
complexes have exhibited potential as photosensitisers [10,
12]. The metal-free analogues have shown no promise as
photosensitisers [12].
Expandedmetallo-porphyrins
Expanded porphyrins have a larger central binding cavity,
increasing the number of potential metals it can accommo-
date.
Diamagnetic metallo-texaphyrins have shown encourag-
ing photophysical properties; high triplet quantum yields
and eﬃcient generation of singlet oxygen [12, 64, 77]. In
particular, the zinc and cadmium derivatives have shown
triplet quantum yields close to unity [12]. In contrast,
the paramagnetic metallo-texaphyrins, Mn-Tex, Sm-Tex,
and Eu-Tex, have undetectable triplet quantum yields. This
behaviour is parallel with that observed for the correspond-
ing metallo-porphyrins [12].
The cadmium-texaphyrin derivative has shown in
vitro photodynamic activity against human leukemia cells
and Gram positive (Staphylococcus) and Gram negative
(Escherichia coli)b a c t e r i a[ 98–101]. Although follow-up
studies have been limited with this photosensitiser due to the
toxicity of the complexed cadmium ion.
A zinc-metallated seco-porphyrazine (Figure 27)h a s
been developed with a high quantum singlet oxygen
yield (ΦΔ 0.74) [102]. This expanded porphyrin-likeLeanne B. Josefsen and Ross W. Boyle 15
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Figure 27: Zinc metallated seco-porphyrazine, platinum, and
palladium derivatives.
photosensitiser has shown the best singlet oxygen photosen-
sitising ability of any of the reported seco-porphyrazines.
Platinum and palladium derivatives have also been synthe-
sised with singlet oxygen quantum yields of 0.59 and 0.54,
respectively, (Figure 27)[ 102].
Metallochlorins/bacteriochlorins
The tin (IV) purpurins were found to be more active
when compared with analogous zinc (II) purpurins, when
evaluated against human cancers [5–7, 9, 18, 103, 104].
Sulphonated benzochlorin derivatives have demon-
strated a reduced phototherapeutic response against murine
leukemia L1210 cells in vitro and transplanted urothelial
cell carcinoma in rats, whereas the tin (IV) metallated
benzochlorins exhibited an increased photodynamic eﬀectin
the same tumour model (Figure 28)[ 105].
The previously mentioned copper octaethylbenzochlorin
(Figure 10) demonstrated an unexpected result. Despite
NH N
N HN
SO3
NN
SnCl2
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Figure 28: Sulphonated and tin (IV) benzochlorin derivatives.
an undetectable triplet state, it appears to be more pho-
toactive towards leukemia cells in vitro and a rat bladder
tumour model [106–108]. Suggestions for this unusual eﬀect
have pointed to interactions between the cationic iminium
group and biomolecules [109]. Such interactions may allow
electron-transfer reactions to take place via the short-lived
excited singlet state and lead to the formation of radicals and
radical ions. The copper-free derivative exhibited a tumour
response with short intervals between drug administration
and photodynamic therapy. Increased in vivo activity was
observed with the zinc benzochlorin analogue [109].
Metallo-phthalocyanines
The photophysical properties of PCs are strongly inﬂuenced
by the presence and nature of the central metal ion [12,
18, 64, 77]. Co-ordination of transition metal ions gives
metallo-complexes with short triplet lifetimes (nanosecond
range), resulting in diﬀerent triplet quantum yields and
lifetimes (with respect to the non-metallated analogues)
[12]. The diamagnetic metals, such as zinc, aluminium,
and gallium, generate metallo-phthalocyanines (MPC) with
high triplet quantum yields (ΦT ≥ 0.4) and short lifetimes
(ZnPCS4 τT = 490Fs and AlPCS4 τT = 400Fs) and high
singlet oxygen quantum yields (ΦΔ ≥ 0.7) [12, 18, 64,
77, 110]. As a result, ZnPC and AlPC have been evaluated
as second generation photosensitisers active against certain
tumours [12].
Metallo-naphthocyaninesulfobenzo-
porphyrazines(M-NSBP)
Aluminium has been successfully coordinated to M-NSBP
(Figure 29). The resulting complex has shown photody-
namic activity against EMT-6 tumour-bearing Balb/c mice
(disulphonatedanaloguedemonstratedgreaterphotoactivity
than the mono-derivative) [111].
Metallo-naphthalocyanines
W¨ ohrle and co-workers (Bulgaria) have concentrated their
investigations on a zinc NC with various amido sub-
stituents. They observed the best phototherapeutic response16 Metal-Based Drugs
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Figure 30: A siloxane naphthalocyanine.
(Lewis lung carcinoma in mice) with a tetrabenzamido
analogue[112–114].Kenney’sgroupintheUSAhavestudied
complexes of silicon (IV) NCs (Figure 30) with two axial
ligands in anticipation the ligands would minimise aggrega-
tion [115]. In particular, they investigated the disubstituted
analogues as potential photodynamic agents [116, 117].
Kenney’s results suggested that a siloxane NC substituted
with two methoxyethyleneglycol ligands is an eﬃcient
photosensitiser against Lewis lung carcinoma in mice and
that SiNC[OSi(i-Bu)2-n-C18H37]2 is eﬀective against Balb/c
mice MS-2 ﬁbrosarcoma cells [118, 119]. van Lier and his
group in Canada have also extensively investigated siloxane
NCs as agents for photodynamic therapy [5, 76]. van
Lier’s research on these compounds suggests that they are
eﬃcaciousphotosensitisersagainstEMT-6tumoursinBalb/c
mice also [120, 121]. The ability of certain metallo-NC
derivatives (AlNc) to generate singlet oxygen is weaker than
theanalogous(sulphonated)metallo-PCs(AlPC);reportedly
1.6–3 orders of magnitude less [12].
Table 1: Quantum triplet yields of texaphyrin metallated with
paramagnetic and diamagnetic lanthanides (data reproduced from
[97]).
Paramagnetic MTex ΦT Diamagnetic MTex
Eu-Tex 0.090 0.563 Y-Tex
Gd-Tex 0.156 0.500 In-Tex
Yb-Tex 0.126 0.340 Lu-Tex
It can be seen from the above examples that generalisa-
tion(s) between the nature of the parent chromophore; the
presence/absence of a central metal ion; and the desirable
photophysical properties required for a successful photo-
sensitiser are diﬃcult to make. In the porphyrin systems,
the zinc ion appears to hinder the photodynamic activity of
the compound; whereas, in the higher/expanded π-systems,
dyes chelated with the same metal ion are observed to form
complexes with good to high photophysical/photodynamic
properties.
Inordertotryandaddresstheseobservations,Sesslerand
his group undertook an extensive study into the metallated
texaphyrins, investigating the “inﬂuence of large metal
cations on the photophysical properties of texaphyrins.”
They particularly studied “the eﬀect of metal cations on the
photophysicalpropertiesofcoordinatingligands.”Thegroup
concentratedonthelanthanide(III)metalions,Y,In,Lu,Cd,
N d ,S m ,E u ,G d ,T b ,D y ,H o ,E r ,T m ,a n dY b[ 97].
Sessler and co-workers observed that when diamagnetic
Lu (III) was complexed to texaphyrin, an eﬀective photo-
sensitiser (Lutex) was generated. When they substituted the
paramagnetic Gd (III) ion for the Lu metal, photodynamic
activity was lost. As a result, the group investigated a range of
diamagnetic and paramagnetic ions [97].
Sessler further reported a correlation between the
excited-singlet and triplet state lifetimes and the rate of ISC
ofthediamagnetictexaphyrincomplexes,Y(III),In(III),and
Lu (III), and the atomic number of the cation [97].
Paramagnetic metallo-texaphyrins were observed to dis-
play rapid ISC. Greater eﬀects on the rates of triplet decay
were also observed, and the triplet lifetimes were strongly
aﬀected by the choice of metal centre [97]. The diamagnetic
ions (Y, In, and Lu) were recorded as having triplet lifetimes
ranging from 187, 126, and 35μs, respectively. Comparable
lifetimes for the paramagnetic species (Eu-Tex 6.98μs, Gd-
Tex 1.11, Tb-Tex < 0.2, Dy-Tex 0.44 × 10
−3,H o - T e x0 .85 ×
10
−3,E r - T e x0 .76 × 10
−3,T m - T e x0 .12 × 10
−3,a n dY b - T e x
0.46) were obtained [97].
Sesslerandhisgroupwereonlyabletomeasurethetriplet
quantum yields for three of the paramagnetic complexes
(see Table 1). The results were signiﬁcantly lower than the
diamagnetic metallo-texaphyrins [97].
The data collected from Sessler and co-workers exper-
iments suggests that, in general, singlet oxygen quantum
yields closely follow the triplet quantum yields.
Their experimental data leads to the conclusion that var-
ious diamagnetic and paramagnetic texaphyrins investigated
have independent photophysical behaviour with respect to
a complex’s magnetism. The diamagnetic complexes wereLeanne B. Josefsen and Ross W. Boyle 17
• ImagingAgents
Imaging agents enhance the detection of certain tissues and can be used as tools in diagnostic
applications including determining the physiology of the body, in managing disease and locating
abnormalities in the body. In particular, certain imaging agents such as the ﬂuorescent
tetrapyrrolic-type photosensitisers described in this Review can aid in determining (photosensitiser)
localisation and degree of photosensitiser uptake by diseased tissue. The main diagnostic imaging
techniques include magnetic resonance imaging (MRI), positron emission tomography (PET),
scintigraphy (radionucleotides), ultrasound imaging, CT scans and x-rays. MRI, PET, and
scintigraphy are well-suited techniques used in medical applications to demonstrate pathological
or physiological alterations in living tissue. Unfortunately, the degree of signal enhancement for
diseased verses normal tissue is often insuﬃcient and the images formed from these techniques do
not adequately show the anatomy or pathology of the desired area. To overcome this problem the
images can be enhanced with contrast enhancement agents.
The contrast agents used for MRI imaging are normally paramagnetic complexes, although
diamagnetic compounds may also be used. The gadolinium-chelates have shown promise as
contrast enhancement agents in pre-clinical trials and clinical use [122]. The gadolinium-enhanced
tissue appears brighter on images in comparison to gadolinium-free tissue. Expanded porphyrins
are particularly suited to co-ordinating these relatively large cations (Gd ionic radius approximately
1.0 ˚ A, expanded porphyrin ionic radius approximately 2.0 ˚ A) in a stable manner [123, 124]. Forming
chelates between a molecule such as an expanded porphyrin and a metal such as gadolinium
reduces the toxicity of the free metal ion [122]. The ﬁrst gadolinium-chelate approved for use as an
enhancement agent was Gd-DTPA (gadopentetate dimeglumine, also known as Magnevist
[125, 126]. Other chelates such as Gd-DOTA (gadoterate meglumine acid, also known as Dotarem
and Gd-Tex have also shown success, with Gd-Tex administered to SMT-F tumour-bearing Balb/c
mice [127, 128].
Metallated porphyrins, including manganese (II) tetraarylporphyrins, have also been studied as
contrast enhancement agents for MRI [12]. Like the expanded porphyrin example above, metals
suited to the technique are generally paramagnetic and include those which are not readily
metabolised by the body and which strongly coordinate to the porphyrin macrocycle.
Diamagnetic agents have also shown some success as gastrointestinal imaging agents, while
superparamagnetic and ferromagnetic agents have been successful for liver and bowel imaging
(Lumirem (Fe2+/3+, bowel), also known as GastroMark, and Endrorem (Fe2+/3+,l i v e r )[ 129].
Other paramagnetic agents include LumenHance (Fe2+,b o w e l )[ 130, 131].
RadiosensitisersandRadiolabels
A number of the metallated photosensitisers described in the Review are also radiosensitisers (see
earlier).
The metallo-photosensitisers have shown further applications as radiolabels. Porphyrins and
phthalocyanines exhibit tumour retention in animals, potentially making them candidates as
carriers of clinically accepted radioisotopes, such as 67Ga (III). 67Ga (III) coordinated to H2PCS
shows good tumour uptake in C3H mice [12, 132]. They have also been used to image the brain,
lymph nodes, melanoma tumours, and as bifunctional chelating agents for antibody labelling.
Examples include 111In, 64Cu, 67Cu, 99mTc (HpD labelled), 57Co-TPP, 109Pd-porphyrins, and 54Mn-
HpD. Vanadium has also been attached to a porphyrin and investigated for PET [12].
PET, also a non-invasive diagnostic imaging technique, produces images of the body’s basic
biochemistry. PET can therefore be useful in observing the body’s biochemical changes aﬀected by
disease. The imaging agents used in PET contain a radioactive material coupled (labeled) to a
compound which is normally present in the body such as water or glucose. The resulting drug
(radionucleotide) is administered to the body and physiological images are formed as the body
processes the drug. Some of the metals used to label the organic molecules include 64Cu and 68Ga
[133, 134]. The latter metal forms a complex which has been used in scans of the meninges—
membrane which surrounds the brain and spinal cord [135].
Box 418 Metal-Based Drugs
Table 2: Summary of a collection of diﬀerent photosensitiser types and their absorption data.
CLASS OF
PHOTOSENSITISER
LONGEST EXTINCTION DRUGS IN DRUGS
WAVELENGTH COEFFICIENT/ CLINICAL TRIAL APPROVED FOR
ABSORPTION/nm M−1cm−1 (Phase I–III) PDT (PRECLINICAL
AND CLINICAL)
Porphyrins 620–640 3,500 —
Photofrin
Levulan
Metvix
(Expanded Porphyrins)
Porphycenes 610–650 50,000 ATMPn
Texaphyrins 730–770 40,000
Lu-Tex
Optrin
Antrin
Xcytrin
Benzvix
Hexvix
Chlorins 650–690 40,000 Foscan Visudyne
Puryltin
Bacteriochlorins 730–800 150,000 — —
Phthalocyanines 680–780 200,000
CGP55847
— PC4
Photosense
Naphthalocyanines 740–780 250,000 — —
Table 3: Summary of a range of photosensitisers and their clinical applications.
TRADE NAME MARKETING COMPANY PRE-/CLINICAL APPLICATION COUNTRIES APPROVED IN
Photofrin QLT Phototherapeutics Oesophageal, lung, bladder and cervical dysplasia
Canada (1993),
The Netherlands (1994),
Japan (1994),
USA (1995),
France (1996),
Germany (1997),
Finland (1999),
UK (1999),
Sweden (2000),
Italy (2000),
Ireland (2000),
Poland (2000)
Levulan DUSA Pharmaceuticals
Actinic keratosis USA (1999),
Actinic keratosis and basal-cell carcinoma Sweden (2001),
Europe (2001)
Metvix Photocure ASA Actinic keratosis and basal-cellcarcinoma Sweden (2001),
Europe (2001)
Visudyne QLT Phototherapeutics
Wet-AMD
Europe (2000),
USA (2000),
Canada (2000),
Subfoveal choroidal neovascularisation
Europe (2000),
USA(2000),
Canada (2000)
ATMPn GlaxoWellcome and Cytopharm Psorasis and non-melanoma skin cancer Germany (1997)
Purlytin Miravant Medical Technologies Psorasis and restenosis USA (1998)
Foscan BioLitec Pharmaceuticals Head and neck cancers Europe (2001)Leanne B. Josefsen and Ross W. Boyle 19
characterised by relatively high ﬂuorescence quantum yields,
excited-singlet and triplet lifetimes, and singlet oxygen
quantum yields; in distinct contrast to the paramagnetic
species investigated [97].
Results suggested that the +2 charged diamagnetic
species exhibit a direct relationship between their ﬂuores-
cence quantum yields, excited state lifetimes, rate of ISC,
and the atomic number of the metal ion. The greatest
diamagnetic ISC rate was observed for Lu-Tex; a result
ascribed to the heavy atom eﬀect. The heavy atom eﬀect
also held for the Y-Tex, In-Tex, and Lu-Tex triplet quantum
yields and lifetimes. The triplet quantum yields and lifetimes
both decreased with increasing atomic number. The singlet
oxygen quantum yield correlated with this observation
[97].
The photophysical properties displayed by the param-
agnetic species were more complex. A simple correlation
between the observed data/behaviour and the number of
unpaired electrons located on the metal ion could not be
made. For example, the ISC rates and the ﬂuorescence
lifetimesgraduallydecreasedwithincreasingatomicnumber,
the Gd-Tex, and Tb-Tex chromophores showed (despite
having a larger number of unpaired electrons) slower rates
of ISC and longer lifetimes than Ho-Tex or Dy-Tex. Sessler
suggested that charge transfer or intermolecular energy
transfer is taking place from higher excited states (such as S2)
[97].
12. SUMMARY
A variety of second generation photosensitisers have been
developed and evaluated against a range of clinical appli-
cations (see Tables 2 and 3). The metallation of a num-
ber of these chromophores has generated a variety of
photosensitisers with improved photophysical properties.
The eﬀectiveness of these metallo-photosensitisers depends
largely (but not deﬁnitively) on the nature of the co-
ordinated central metal ion. Chromophores chelated to
diamagnetic transition metals and lanthanide ions have
shown the greatest potential as photodynamic agents, a
consequence of the heavy metal eﬀect enhancing the rate of
ISC. As a result, a number of these metallated tetrapyrrole-
based macrocycles are currently photosensitisers of choice,
particularly the zinc (II), aluminium (III), and tin (IV)
complexes.
GLOSSARY
1. AMD is the leading cause of blindness in humans over
the age of 50. AMD is characterised by a rapid growth of
abnormal blood vessels under the central retina causing
scarring, and an accelerated loss of visual acuity [58].
2. Chemosensitisers are drugs or chemicals which are
used to enhance the therapeutic eﬀects of anti-cancer
(chemotherapy) drugs. They make the tumour cells
more sensitive to the eﬀects of chemotherapy.
3. Diamagnetic species is a species with no unpaired
electrons, that is, all electrons are spin-paired.
4. Fluorophore is generally a molecule capable of absorb-
ing light energy when irradiated at a speciﬁc wavelength
and emitting energy at longer wavelengths.
5. Heavy atom eﬀect enhances coupling between the
excited-singlet (S1) and excited-triplet (T1) states. It
is the enhancement of a spin-forbidden process by
the presence of an atom of high atomic molecular
weight. Mechanistically, it responds to a spin-orbit
couplingenhancementproducedbyaheavyatom.Spin-
forbidden and spin-allowed processes are highlighted in
Section 7.
6. Luminescence lifetime is the average time a molecule
spends in an excited state (Sn > 0o rT n > 0).
7. Methylene blue is used to sterilize/decontaminate
freshly frozen plasma units by inactivating extracel-
lularly enveloped viruses (such as HIV), as well as
methaemoglobinaemia [5, 9].
8. Paramagnetic species is a species with one or more
unpaired electrons.
9. Phase I clinical trials are used to determine phar-
macokinetic properties (metabolism, elimination, and
preferred method of administration) and a safe dosage
range, and identify any side eﬀects of a new drug. They
are performed on a small number of people (20–80).
10. PhaseIIclinicaltrialsareperformedonalargergroupof
people (100–300). The drug is further evaluated to test
its eﬀectiveness and any side eﬀects.
11. Phase III clinical trials: the drugs eﬀectiveness is con-
ﬁrmed and comparisons are made to more commonly
used treatment modalities in a range of 1000–3000
people. Potential side eﬀects are monitored.
12. Phase IV clinical trials are post-marketing observations
and evaluations.
13. Photochemotherapy is a combination of a chemical
substance and light to treat disease.
14. Phototherapy is a term used to describe the treatment
of disease by a series of (photo-) chemical processes
initiated by light.
15. Radiosensitisers are drugs which boost the eﬀect of
radiation therapy (radiotherapy) by making the tumour
tissue more vulnerable to the applied radiation. They
may be used alone or in conjunction with other drugs.
16. Restenosis is the renarrowing of a coronary artery after
angioplasty or stenting.
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